DelveInsight, a leading market research and consulting company, announces the release of its latest report, “PROTAC Market Size, Target Population, Competitive Landscape & Market Forecast – 2036.” The report provides a comprehensive understanding of the PROTAC market, including target patient population analysis, emerging therapies, competitive landscape, market trends, market size, market share, technology assessment, pricing dynamics, and future opportunities across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.
Key Takeaways from the PROTAC Market
The PROTAC market is expected to witness substantial growth during the forecast period 2022–2036.
The total PROTAC market size is projected to increase from approximately USD 10 billion in 2028 to nearly USD 16 billion by 2036.
PROTACs represent one of the most promising targeted protein degradation technologies, offering the ability to degrade disease-causing proteins rather than simply inhibiting them.
In 2019, Bavdegalutamide (ARV-110) became the first PROTAC molecule to enter clinical development, establishing clinical proof-of-concept for the modality.
Key indications driving the PROTAC market include HR+/HER2− Breast Cancer, Triple Negative Breast Cancer (TNBC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Colorectal Cancer, and Non-Small Cell Lung Cancer (NSCLC).
In 2025, the United States reported approximately 215,000 incident cases of HR+/HER2− Breast Cancer, 47,000 incident TNBC cases, 54,000 prevalent mCRPC cases, 154,000 incident colorectal cancer cases, and 207,000 incident NSCLC cases, representing significant addressable populations for PROTAC therapies.
Leading PROTAC companies include Arvinas, Pfizer, Novartis, Astellas Pharma, and Dialectic Therapeutics, among others.
Key emerging PROTAC therapies include Vepdegestrant (ARV-471), Luxdegalutamide (ARV-766), ASP3082, and DT2216.
Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/protac-market-forecast
Key Factors Driving the PROTAC Market
Rising Interest in Targeted Protein Degradation
PROTACs are revolutionizing drug development by enabling selective degradation of disease-causing proteins rather than conventional inhibition. This approach provides opportunities to target proteins previously considered undruggable, expanding therapeutic possibilities across multiple disease areas.
Expanding Applications in Oncology
The majority of clinical-stage PROTACs are being developed for oncology indications, particularly breast cancer, prostate cancer, colorectal cancer, and lung cancer. Growing cancer incidence and demand for precision therapies continue to support market expansion.
Ability to Overcome Drug Resistance
One of the major advantages of PROTAC technology is its potential to overcome resistance mechanisms associated with conventional therapies by degrading the target protein rather than simply blocking its activity.
Increasing Strategic Collaborations
Major partnerships such as Arvinas-Pfizer and Arvinas-Novartis demonstrate growing pharmaceutical industry confidence in PROTAC technology and are accelerating development and commercialization activities.
PROTAC Competitive Landscape
Several PROTAC therapies are advancing through clinical development, with oncology remaining the primary focus area. Leading companies including Arvinas, Pfizer, Novartis, Astellas Pharma, and Dialectic Therapeutics are actively developing innovative targeted protein degraders across multiple cancer indications.
The most advanced PROTAC candidates include Vepdegestrant (ARV-471), Luxdegalutamide (ARV-766), ASP3082, and DT2216. These therapies target diverse proteins including estrogen receptor (ER), androgen receptor (AR), and KRAS G12D, aiming to improve efficacy, overcome resistance mechanisms, and expand treatment options for patients with difficult-to-treat cancers.
Discover more about therapies set to grab major PROTAC market share @ PROTAC Clinical Trials and Therapeutic Assessment.
Recent Developments in the PROTAC Market
In October 2025, Arvinas announced new patient-reported outcomes data from the Phase III VERITAC-2 trial evaluating Vepdegestrant, presented at the 2025 ESMO Congress.
In November 2025, Arvinas presented multiple Vepdegestrant-related abstracts at the San Antonio Breast Cancer Symposium (SABCS).
In March 2025, Arvinas and Pfizer reported positive topline results from the Phase III VERITAC-2 study, demonstrating significant progression-free survival improvement in ESR1-mutant breast cancer patients.
In September 2024, Astellas Pharma reported encouraging preliminary safety and efficacy data for ASP3082 in advanced pancreatic cancer, colorectal cancer, and NSCLC patients carrying KRAS G12D mutations.
In April 2024, Arvinas entered into an exclusive global licensing agreement with Novartis for the development and commercialization of Luxdegalutamide (ARV-766).
What are PROTACs?
Proteolysis Targeting Chimeras (PROTACs) are bifunctional small molecules designed to selectively degrade disease-causing proteins through the ubiquitin-proteasome system. A PROTAC molecule consists of a target protein ligand, a linker, and an E3 ligase ligand. Unlike traditional inhibitors that block protein function, PROTACs trigger complete degradation of the target protein, offering a potentially more durable therapeutic effect and expanding the range of druggable targets.
PROTAC Target Population Segmentation
The PROTAC market report evaluates target populations across major oncology indications, including:
HR+/HER2− Breast Cancer
Triple Negative Breast Cancer (TNBC)
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Colorectal Cancer (mCRC)
Non-Small Cell Lung Cancer (NSCLC)
Other Emerging Oncology Indications
Total Eligible Patient Pool for PROTAC Therapies
Total Treated Cases in Selected Indications
Scope of the PROTAC Market Report
Therapeutic Assessment: Emerging PROTAC Therapies
PROTAC Market Dynamics: Drivers, Barriers, Opportunities, and Future Trends
Key Companies: Arvinas, Pfizer, Novartis, Astellas Pharma, Dialectic Therapeutics, and others
Key Therapies: Vepdegestrant, Luxdegalutamide, ASP3082, DT2216, and others
Competitive Intelligence Analysis: SWOT Analysis and Market Entry Strategies
PROTAC Market Size, Market Share, Industry Trends, and Forecast Analysis
Technology Assessment and Innovation Landscape
Pricing Trends and Analogue Analysis
KOL Perspectives, Analyst Views, Market Access, and Reimbursement Assessment
To know more about PROTAC companies working in the treatment market, visit @ PROTAC Clinical Trials and Therapeutic AssessmentTable of Contents
PROTAC Market Report Introduction
Executive Summary for PROTAC
PROTAC Market Overview at a Glance
Technology Assessment of PROTAC Therapies
Target Population and Epidemiology Analysis
Emerging PROTAC Therapies
Vepdegestrant (ARV-471): Arvinas and Pfizer
Luxdegalutamide (ARV-766): Arvinas and Novartis
ASP3082: Astellas Pharma
Competitive Landscape
Clinical Trial Analysis
Conjoint Analysis
Market Outlook
Country-wise PROTAC Market Analysis (2022–2036)
Market Size by Indication
Market Size by Therapy
Market Access and Reimbursement
Pricing Trends and Analogue Assessment
KOL Perspectives
SWOT Analysis
Unmet Needs
Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through its subscription-based platform PharmDelve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kirti SharmaEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
